- 25I-NB34MD
- N-(3,4-Methylenedioxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine
- N-[(2H-1,3-Benzodioxol-5-yl)methyl]-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine
- N-(1,3-Benzodioxol-5-ylmethyl)-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine
Braden, MR. Towards a biophysical understanding of hallucinogen action Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8.4 MB. #25I-NB34MD
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #13
Nichols, DE. Chemistry and structure–activity relationships of psychedelics In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 1-43. 2.6 MB. https://doi.org/10.1007/7854_2017_475 #Table 3: 3,4-OCH2O
Nichols, DE. Structure-activity relationships of serotonin 5-HT2A agonists WIREs Membr. Transp. Signal, 1 Sep 2012, 1 (5), 559-579. 573 kB. https://doi.org/10.1002/wmts.42
Uchiyama, N; Kikura-Hanajiri, R; Hakamatsuka, T. A phenethylamine derivative 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(3,4-methylenedioxyphenyl)methyl]ethanamine (25I-NB34MD) and a piperazine derivative 1-(3,4-difluoromethylenedioxybenzyl)piperazine (DF-MDBP), newly detected in illicit products Forensic Toxicol., 1 Jan 2016, 34 (1), 166–173. 1.0 MB. https://doi.org/10.1007/s11419-015-0304-7 #1 LC,MS,NMR,UV